us clinical guidance

Emergency contraception

CDC U.S. SPR timing, method selection, post-ulipristal contraception and follow-up after emergency contraception.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

People at risk of pregnancy after recent unprotected intercourse, contraceptive failure or sexual assault. Emergency contraception prevents pregnancy after intercourse; it does not end an established pregnancy, prevent sexually transmitted infection or substitute for assault-informed medical care.
sources for this section:CDC U.S. SPR 2024CDC U.S. MEC 2024

The Bottom Line

  • Offer emergency contraception as soon as possible and within five days of unprotected intercourse; efficacy and method suitability differ across the five-day window.
  • A copper intrauterine device placed within the recommended timing is highly effective emergency contraception and can continue as ongoing contraception when insertion is acceptable and medically eligible.
  • Ulipristal acetate generally retains greater effectiveness than levonorgestrel later in the five-day window, while body weight and access may affect oral-method counseling without justifying refusal of care.
  • After ulipristal, delay starting or resuming a progestin-containing method for five days because simultaneous progestin may reduce ulipristal effectiveness; use barrier protection during the transition.
  • After levonorgestrel emergency contraception, a regular method can start immediately with the method-specific backup period described in U.S. SPR.
sources for this section:CDC U.S. SPR 2024CDC U.S. MEC 2024

Practical clinical workflow

1
Establish the timing of every recent unprotected exposure, usual cycle pattern, current contraception, pregnancy possibility, medications, desired ongoing method and need for confidential or assault-informed care.
2
Explain copper-IUD and oral options with timing, expected efficacy, weight evidence, contraindications, access, cost and whether the patient wants ongoing intrauterine contraception.
3
Provide the selected method without requiring an unnecessary examination or pregnancy test when oral emergency contraception is appropriate; do not withhold pills solely because pregnancy cannot yet be excluded.
4
Give written instructions for starting ongoing contraception, required backup, expected bleeding change, vomiting after a dose and how to obtain another dose or urgent review.
5
Arrange a pregnancy test if no withdrawal bleed occurs within three weeks, and offer sexually transmitted infection testing, condoms and advance provision of emergency contraception where appropriate.
sources for this section:CDC U.S. SPR 2024CDC U.S. MEC 2024

Safety boundaries and escalation

  • Severe or one-sided abdominal pain, syncope, shoulder-tip pain or heavy bleeding after a missed period requires urgent assessment for ectopic pregnancy or another emergency.
  • Enzyme-inducing medicines can reduce oral emergency-contraception exposure; check current product labeling and prioritize an effective noninteracting option when eligible.
  • An intrauterine device is not inserted for emergency contraception in a patient with current purulent cervicitis or known untreated chlamydial or gonococcal infection; same-day screening can otherwise occur without automatic delay.
  • Sexual assault requires consent-led forensic, infection-prophylaxis, safety and support options in addition to pregnancy prevention; emergency contraception alone is not complete care.
sources for this section:CDC U.S. SPR 2024CDC U.S. MEC 2024

Localization

This summary follows CDC U.S. SPR and U.S. MEC. Prescription status, pharmacy stocking, age-neutral access, insurance coverage and same-day IUD availability vary across US settings; local assault and safeguarding pathways apply.
sources for this section:CDC U.S. SPR 2024CDC U.S. MEC 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionU.S. Selected Practice Recommendations for Contraceptive Use, 2024MMWR 2024;73(No. RR-3); DOI 10.15585/mmwr.rr7303a1 路 published 2024-08-08 路 accessed 2026-08-20
    view source
  2. Centers for Disease Control and PreventionU.S. Medical Eligibility Criteria for Contraceptive Use, 2024MMWR 2024;73(No. RR-4); DOI 10.15585/mmwr.rr7304a1 路 published 2024-08-08 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.